These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

428 related articles for article (PubMed ID: 18314943)

  • 21. Rapid generation of a high quality lead for transforming growth factor-beta (TGF-beta) type I receptor (ALK5).
    Goldberg FW; Ward RA; Powell SJ; Debreczeni JE; Norman RA; Roberts NJ; Dishington AP; Gingell HJ; Wickson KF; Roberts AL
    J Med Chem; 2009 Dec; 52(23):7901-5. PubMed ID: 19736928
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Hybrid inhibitors of phosphatidylinositol 3-kinase (PI3K) and the mammalian target of rapamycin (mTOR): design, synthesis, and superior antitumor activity of novel wortmannin-rapamycin conjugates.
    Ayral-Kaloustian S; Gu J; Lucas J; Cinque M; Gaydos C; Zask A; Chaudhary I; Wang J; Di L; Young M; Ruppen M; Mansour TS; Gibbons JJ; Yu K
    J Med Chem; 2010 Jan; 53(1):452-9. PubMed ID: 19928864
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Discovery of 4-{4-[3-(pyridin-2-yl)-1H-pyrazol-4-yl]pyridin-2-yl}-N-(tetrahydro-2H- pyran-4-yl)benzamide (GW788388): a potent, selective, and orally active transforming growth factor-beta type I receptor inhibitor.
    Gellibert F; de Gouville AC; Woolven J; Mathews N; Nguyen VL; Bertho-Ruault C; Patikis A; Grygielko ET; Laping NJ; Huet S
    J Med Chem; 2006 Apr; 49(7):2210-21. PubMed ID: 16570917
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Optimization of 6,6-dimethyl pyrrolo[3,4-c]pyrazoles: Identification of PHA-793887, a potent CDK inhibitor suitable for intravenous dosing.
    Brasca MG; Albanese C; Alzani R; Amici R; Avanzi N; Ballinari D; Bischoff J; Borghi D; Casale E; Croci V; Fiorentini F; Isacchi A; Mercurio C; Nesi M; Orsini P; Pastori W; Pesenti E; Pevarello P; Roussel P; Varasi M; Volpi D; Vulpetti A; Ciomei M
    Bioorg Med Chem; 2010 Mar; 18(5):1844-53. PubMed ID: 20153204
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pharmacophore modeling and virtual screening for the discovery of new transforming growth factor-beta type I receptor (ALK5) inhibitors.
    Ren JX; Li LL; Zou J; Yang L; Yang JL; Yang SY
    Eur J Med Chem; 2009 Nov; 44(11):4259-65. PubMed ID: 19640613
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Synthesis and biological evaluation of 4(5)-(6-methylpyridin-2-yl)imidazoles and -pyrazoles as transforming growth factor-beta type 1 receptor kinase inhibitors.
    Kim DK; Lee YI; Lee YW; Dewang PM; Sheen YY; Kim YW; Park HJ; Yoo J; Lee HS; Kim YK
    Bioorg Med Chem; 2010 Jun; 18(12):4459-67. PubMed ID: 20472445
    [TBL] [Abstract][Full Text] [Related]  

  • 27. ATP-competitive inhibitors of the mammalian target of rapamycin: design and synthesis of highly potent and selective pyrazolopyrimidines.
    Zask A; Verheijen JC; Curran K; Kaplan J; Richard DJ; Nowak P; Malwitz DJ; Brooijmans N; Bard J; Svenson K; Lucas J; Toral-Barza L; Zhang WG; Hollander I; Gibbons JJ; Abraham RT; Ayral-Kaloustian S; Mansour TS; Yu K
    J Med Chem; 2009 Aug; 52(16):5013-6. PubMed ID: 19645448
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Design of novel quinazoline derivatives and related analogues as potent and selective ALK5 inhibitors.
    Gellibert F; Fouchet MH; Nguyen VL; Wang R; Krysa G; de Gouville AC; Huet S; Dodic N
    Bioorg Med Chem Lett; 2009 Apr; 19(8):2277-81. PubMed ID: 19285388
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Synthesis and biological evaluation of 1-substituted-3(5)-(6-methylpyridin-2-yl)-4-(quinoxalin-6-yl)pyrazoles as transforming growth factor-β type 1 receptor kinase inhibitors.
    Jin CH; Sreenu D; Krishnaiah M; Subrahmanyam VB; Rao KS; Nagendra Mohan AV; Park CY; Son JY; Son DH; Park HJ; Sheen YY; Kim DK
    Eur J Med Chem; 2011 Sep; 46(9):3917-25. PubMed ID: 21696866
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Novel and potent transforming growth factor beta type I receptor kinase domain inhibitor: 7-amino 4-(2-pyridin-2-yl-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl)-quinolines.
    Li HY; Wang Y; Yan L; Campbell RM; Anderson BD; Wagner JR; Yingling JM
    Bioorg Med Chem Lett; 2004 Jul; 14(13):3585-8. PubMed ID: 15177480
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pyrazole diaminopyrimidines as dual inhibitors of KDR and Aurora B kinases.
    Curtin ML; Heyman HR; Frey RR; Marcotte PA; Glaser KB; Jankowski JR; Magoc TJ; Albert DH; Olson AM; Reuter DR; Bouska JJ; Montgomery DA; Palma JP; Donawho CK; Stewart KD; Tse C; Michaelides MR
    Bioorg Med Chem Lett; 2012 Jul; 22(14):4750-5. PubMed ID: 22695126
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Stopping replication, at the beginning.
    Jackson PK
    Nat Chem Biol; 2008 Jun; 4(6):331-2. PubMed ID: 18488006
    [No Abstract]   [Full Text] [Related]  

  • 33. Discovery of a potent and orally bioavailable benzolactam-derived inhibitor of Polo-like kinase 1 (MLN0905).
    Duffey MO; Vos TJ; Adams R; Alley J; Anthony J; Barrett C; Bharathan I; Bowman D; Bump NJ; Chau R; Cullis C; Driscoll DL; Elder A; Forsyth N; Frazer J; Guo J; Guo L; Hyer ML; Janowick D; Kulkarni B; Lai SJ; Lasky K; Li G; Li J; Liao D; Little J; Peng B; Qian MG; Reynolds DJ; Rezaei M; Scott MP; Sells TB; Shinde V; Shi QJ; Sintchak MD; Soucy F; Sprott KT; Stroud SG; Nestor M; Visiers I; Weatherhead G; Ye Y; D'Amore N
    J Med Chem; 2012 Jan; 55(1):197-208. PubMed ID: 22070629
    [TBL] [Abstract][Full Text] [Related]  

  • 34. SM16, an orally active TGF-beta type I receptor inhibitor prevents myofibroblast induction and vascular fibrosis in the rat carotid injury model.
    Fu K; Corbley MJ; Sun L; Friedman JE; Shan F; Papadatos JL; Costa D; Lutterodt F; Sweigard H; Bowes S; Choi M; Boriack-Sjodin PA; Arduini RM; Sun D; Newman MN; Zhang X; Mead JN; Chuaqui CE; Cheung HK; Zhang X; Cornebise M; Carter MB; Josiah S; Singh J; Lee WC; Gill A; Ling LE
    Arterioscler Thromb Vasc Biol; 2008 Apr; 28(4):665-71. PubMed ID: 18202322
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pyrazolone based TGFbetaR1 kinase inhibitors.
    Guckian K; Carter MB; Lin EY; Choi M; Sun L; Boriack-Sjodin PA; Chuaqui C; Lane B; Cheung K; Ling L; Lee WC
    Bioorg Med Chem Lett; 2010 Jan; 20(1):326-9. PubMed ID: 19914068
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Synthesis and biological evaluation of 1-substituted-3(5)-(6-methylpyridin-2-yl)-4-(quinolin-6-yl)pyrazoles as transforming growth factor-β type 1 receptor kinase inhibitors.
    Jin CH; Krishnaiah M; Sreenu D; Rao KS; Subrahmanyam VB; Park CY; Son JY; Sheen YY; Kim DK
    Bioorg Med Chem; 2011 Apr; 19(8):2633-40. PubMed ID: 21435890
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Design, synthesis, and evaluation of indolinones as inhibitors of the transforming growth factor β receptor I (TGFβRI).
    Roth GJ; Heckel A; Brandl T; Grauert M; Hoerer S; Kley JT; Schnapp G; Baum P; Mennerich D; Schnapp A; Park JE
    J Med Chem; 2010 Oct; 53(20):7287-95. PubMed ID: 20919678
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Discovery of orally bioavailable imidazo[1,2-a]pyrazine-based Aurora kinase inhibitors.
    Belanger DB; Williams MJ; Curran PJ; Mandal AK; Meng Z; Rainka MP; Yu T; Shih NY; Siddiqui MA; Liu M; Tevar S; Lee S; Liang L; Gray K; Yaremko B; Jones J; Smith EB; Prelusky DB; Basso AD
    Bioorg Med Chem Lett; 2010 Nov; 20(22):6739-43. PubMed ID: 20855207
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Discovery of highly potent, selective, and efficacious small molecule inhibitors of ERK1/2.
    Ren L; Grina J; Moreno D; Blake JF; Gaudino JJ; Garrey R; Metcalf AT; Burkard M; Martinson M; Rasor K; Chen H; Dean B; Gould SE; Pacheco P; Shahidi-Latham S; Yin J; West K; Wang W; Moffat JG; Schwarz JB
    J Med Chem; 2015 Feb; 58(4):1976-91. PubMed ID: 25603482
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Design and optimization of potent and orally bioavailable tetrahydronaphthalene Raf inhibitors.
    Gould AE; Adams R; Adhikari S; Aertgeerts K; Afroze R; Blackburn C; Calderwood EF; Chau R; Chouitar J; Duffey MO; England DB; Farrer C; Forsyth N; Garcia K; Gaulin J; Greenspan PD; Guo R; Harrison SJ; Huang SC; Iartchouk N; Janowick D; Kim MS; Kulkarni B; Langston SP; Liu JX; Ma LT; Menon S; Mizutani H; Paske E; Renou CC; Rezaei M; Rowland RS; Sintchak MD; Smith MD; Stroud SG; Tregay M; Tian Y; Veiby OP; Vos TJ; Vyskocil S; Williams J; Xu T; Yang JJ; Yano J; Zeng H; Zhang DM; Zhang Q; Galvin KM
    J Med Chem; 2011 Mar; 54(6):1836-46. PubMed ID: 21341678
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.